Jefferies lowered the firm’s price target on Syndax (SNDX) to $37 from $40 and keeps a Buy rating on the shares following Q1 results. The firm noted that the revuforj revenue miss was due to approximately 50% of KMT2A patients going to transplant. On the other hand, Jefferies told investors that the major silver lining is that these revenues should come back over time with post-transplant maintenance, plus NPM1 patient adds growing nicely.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Analyst Reiterates Buy on Syndax as Commercial Momentum Builds and Clinical Data Strengthens, Maintains $40 Price Target
- Syndax price target raised to $37 from $35 at Barclays
- Phil Nadeau Reiterates Buy on Syndax, Citing Strong Revuforj Momentum, Longer Treatment Durations, and Emerging Niktimvo Upside
- Syndax reports Q1 EPS (48c), consensus (59c)
- Syndax price target raised to $34 from $28 at Goldman Sachs